High cancer drug prices significantly contribute to health care costs in the United States, with the average annual price of new cancer drugs increasing from less than $10,000 before 2000 to $145,000 in 2015. Baker Institute fellows Hagop M. Kantarjian and Vivian Ho highlight this issue and propose possible solutions.
This policy brief is part of a series of recommendations from the Baker Institute for the incoming president’s administration.
